FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product

📆 2024-05-31 17:27:00
📰 NBCNewYork

⏱ Reading Time:
27 sec. here
2 min. at publisher
📊 Quality Score:
News: 14%
Publisher: 63%

Sverige Nyheter Nyheter

Sverige Senaste nytt,Sverige Rubriker

The decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only commercially available product.

The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand for its Covid jab, its only commercially available product.

A positive recommendation from the CDC would allow Moderna's vaccine to compete against GSK and Pfizer, which launched their respective shots in the U.S. last fall. Pfizer's vaccine has so far lagged behind GSK's, but both shots have so far recorded hundreds of millions in sales.The approval demonstrates the versatility of Moderna's messenger RNA platform beyond treating Covid.

Moderna has said it expects to return to sales growth in 2025 and to break even by 2026, with the launch of new products.

Skriv Kommentar

Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer:

Sverige Senaste nytt, Sverige Rubriker

Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.

FDA approves Moderna's RSV vaccine for seniors, the company's second-ever productThe decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only commercially available product.
Källa: CNBC - 🏆 12. / 72 Läs mer »